Detail akcie Bioline RX Sp ADR online

Business Summary: BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Financial Summary: BRIEF: For the three months ended 31 March 2024, BioLine RX Ltd - ADR revenues increased from $0K to $6.9M. Net loss decreased 94% to $696K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Non-operating Income/Expenses, Net increase from $2.9M (expense) to $4.5M (income), Research and development expenses decrease of 32% to $2.5M (expense).